vs
Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and Arcus Biosciences, Inc. (RCUS), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Arcus Biosciences, Inc. is the larger business by last-quarter revenue ($11.0M vs $906.0K, roughly 12.1× Mind Medicine (MindMed) Inc.). Arcus Biosciences, Inc. runs the higher net margin — -2634.0% vs -963.6%, a 1670.4% gap on every dollar of revenue. On growth, Mind Medicine (MindMed) Inc. posted the faster year-over-year revenue change (-16.1% vs -52.2%).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
DFTX vs RCUS — Head-to-Head
Income Statement — Q4 2023 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $906.0K | $11.0M |
| Net Profit | $-23.9M | $-106.0M |
| Gross Margin | — | — |
| Operating Margin | -2450.8% | -1036.4% |
| Net Margin | -2634.0% | -963.6% |
| Revenue YoY | -16.1% | -52.2% |
| Net Profit YoY | -386.7% | -12.8% |
| EPS (diluted) | $-0.58 | $-0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | — | $11.0M | ||
| Q3 25 | — | $6.0M | ||
| Q2 25 | — | $8.0M | ||
| Q1 25 | — | $8.0M | ||
| Q4 24 | — | $23.0M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | $10.0M |
| Q4 25 | — | $-106.0M | ||
| Q3 25 | — | $-135.0M | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $-112.0M | ||
| Q4 24 | — | $-94.0M | ||
| Q3 24 | — | $-92.0M | ||
| Q2 24 | — | $-93.0M | ||
| Q1 24 | — | $-4.0M |
| Q4 25 | — | -1036.4% | ||
| Q3 25 | — | -2366.7% | ||
| Q2 25 | — | -100.0% | ||
| Q1 25 | — | -1525.0% | ||
| Q4 24 | — | -447.8% | ||
| Q3 24 | — | -1500.0% | ||
| Q2 24 | — | -963.6% | ||
| Q1 24 | — | -160.0% |
| Q4 25 | — | -963.6% | ||
| Q3 25 | — | -2250.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -1400.0% | ||
| Q4 24 | — | -408.7% | ||
| Q3 24 | — | -1314.3% | ||
| Q2 24 | — | -845.5% | ||
| Q1 24 | — | -40.0% |
| Q4 25 | — | $-0.88 | ||
| Q3 25 | — | $-1.27 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-1.14 | ||
| Q4 24 | — | $-1.07 | ||
| Q3 24 | — | $-1.00 | ||
| Q2 24 | — | $-1.02 | ||
| Q1 24 | — | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.7M | $222.0M |
| Total DebtLower is stronger | — | $99.0M |
| Stockholders' EquityBook value | $78.1M | $631.0M |
| Total Assets | $124.5M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.16× |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | — | $222.0M | ||
| Q3 25 | — | $238.0M | ||
| Q2 25 | — | $248.0M | ||
| Q1 25 | — | $192.0M | ||
| Q4 24 | — | $150.0M | ||
| Q3 24 | — | $201.0M | ||
| Q2 24 | — | $156.0M | ||
| Q1 24 | — | $185.0M |
| Q4 25 | — | $99.0M | ||
| Q3 25 | — | $98.0M | ||
| Q2 25 | — | $97.0M | ||
| Q1 25 | — | $48.0M | ||
| Q4 24 | — | $48.0M | ||
| Q3 24 | — | $47.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $631.0M | ||
| Q3 25 | — | $436.0M | ||
| Q2 25 | — | $549.0M | ||
| Q1 25 | — | $531.0M | ||
| Q4 24 | — | $485.0M | ||
| Q3 24 | — | $565.0M | ||
| Q2 24 | — | $635.0M | ||
| Q1 24 | — | $707.0M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $974.0M | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.3B |
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.09× | ||
| Q4 24 | — | 0.10× | ||
| Q3 24 | — | 0.08× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.6M | $-120.0M |
| Free Cash FlowOCF − Capex | — | $-121.0M |
| FCF MarginFCF / Revenue | — | -1100.0% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | — | 9.1% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | — | $-120.0M | ||
| Q3 25 | — | $-97.0M | ||
| Q2 25 | — | $-133.0M | ||
| Q1 25 | — | $-132.0M | ||
| Q4 24 | — | $-100.0M | ||
| Q3 24 | — | $26.0M | ||
| Q2 24 | — | $-94.0M | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | — | $-121.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-133.0M | ||
| Q4 24 | — | $-101.0M | ||
| Q3 24 | — | $25.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-6.0M |
| Q4 25 | — | -1100.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -1662.5% | ||
| Q4 24 | — | -439.1% | ||
| Q3 24 | — | 357.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -60.0% |
| Q4 25 | — | 9.1% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 12.5% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 40.0% |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
DFTX
Segment breakdown not available.
RCUS
| Other | $5.0M | 45% |
| Other Collaboration Revenue | $4.0M | 36% |
| Access Rights And Option Continuation Periods | $2.0M | 18% |
